Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Curr+Respir+Med+Rev 2015 ; 11 (2): 163-74 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Outcome Measures for Clinical Trials in Interstitial Lung Diseases #MMPMID27019654
Lammi MR; Baughman RP; Birring SS; Russell AM; Ryu JH; Scholand M; Distler O; LeSage D; Sarver C; Antoniou K; Highland KB; Kowal-Bielecka O; Lasky JA; Wells AU; Saketkoo LA
Curr Respir Med Rev 2015[]; 11 (2): 163-74 PMID27019654show ga
The chronic fibrosing idiopathic interstitial pneumonias (IIPs) are a group of heterogeneous pulmonary parenchymal disorders described by radiologic and histological patterns termed usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP). These include idiopathic pulmonary fibrosis (IPF) and those related to connective tissue disease (CTD) and are associated with substantial morbidity and mortality. Beyond the importance of establishing an appropriate diagnosis, designing optimal clinical trials for IIPs has been fraught with difficulties in consistency of clinical endpoints making power analyses, and the establishment of efficacy and interpretation of results across trials challenging.Preliminary recommendations, developed by rigorous consensus methods, proposed a minimum set of outcome measures, a ?core set?, to be incorporated into future clinical trials (Saketkoo et al, THORAX. 2014.). This paper sets out to examine the candidate instruments for each domain (Dyspnea, Cough, Health Related Quality of Life, Imaging, Lung Physiology and Function, Mortality). Candidate measures that were not selected as well as measures that were not available for examination at the time of the consensus process will also be discussed.
free
free
free
Curr+Respir+Med+Rev 2015 ; 11 (2): 163-74
